Measurement and Meaning: Why Patient-Centered Outcomes are a Key Piece of the Development Puzzle

The foremost priority of any biotech or pharmaceutical company is clear: demonstrate that your product works, that it is safe, and that it meets an identifiable need. In a resource-constrained environment, it is essential that any activity can be justified in terms of its ability to support this goal. However, clinical development teams increasingly face significant challenges related not only to their available time and budgets, but also increasing regulatory scrutiny, investor expectations, ever-changing market conditions, and competitor pressures. It is understandable then that despite best efforts, companies often fail to adequately consider how their evidence generation strategy might best meet the needs of all stakeholders in the development process.

Smaller companies in particular are faced with difficult decisions in terms of directing their clinical development thinking. A strong biological rationale, promising clinical signal, or novel mechanism of action may not prove sufficient to secure either regulatory approval or market access, or the product differentiation needed to realize the commercial potential of a newly developed treatment. It is no longer enough to show that a treatment has an effect ‒ the emphasis is now on demonstrating why that effect matters to patients, clinicians, payers, and healthcare systems. Patient-centered outcomes provide one mean by which such questions can be addressed.

Are you measuring what matters?

Endpoint selection is one of the most common challenges in clinical development. Historically, many sponsors have relied on precedent from earlier trials and approaches used by competitors. This is an increasingly risky proposition for a number of reasons.

Firstly, the regulatory environment is constantly evolving and the focus of attention moves with it. The extent to which an endpoint reflects symptoms or impacts that patients consider meaningful is inarguably now a central concern. What do statistically significant changes mean for patients and how do these impact their daily lives? Are the assessments used sensitive to all relevant aspects of disease burden? What are the implications for the degree of healthcare or social support a patient may require? These are not abstract questions and the answers can influence trial design, interpretation of results, product positioning, and the strength of evidence available for regulators and health technology assessment (HTA) bodies.

Secondly, by relying on existing approaches that were developed with different products in mind, there is a significant risk that outcomes and benefits associated with a new treatment are understated or even ignored completely. An effective endpoint strategy should be tailored to the specific context accounting for all relevant considerations. Establishing the right endpoint strategy maximizes the likelihood that you can fully recognize the potential value of a given treatment.

What is your unique selling point?

Many therapeutic areas are becoming increasingly competitive. New entrants may face multiple products with similar mechanisms or more established products with extensive real-world evidence and market access. In these contexts, differentiation can be difficult to achieve based on efficacy data alone.

Patient-centered evidence can help clarify why a product is different in ways that matter. This might involve reduced symptom burden, improved functioning, increased tolerability, greater convenience, or benefits for subgroups who are underserved by existing treatment options. These aspects can help support the development of a more compelling value proposition, particularly where clinical differences between products are perhaps modest.

It is essential to remember that for claims about patient benefit to be credible, they must be supported by robust evidence. It is not sufficient to merely suggest that a product should be preferred by patients; it needs to be successfully demonstrated. Sponsors who fail to adequately consider their patient evidence needs may find that they lack the data or appropriate trial design to support such a product narrative. Early planning can allow sponsors to map their evidence requirements and ensure that they are prepared for future regulatory, HTA, and payer discussions.

Are you maximizing your return on investment?

Clinical trials are expensive, time-consuming, and logistically complex to organize and execute. It is therefore important that sponsors utilize every opportunity to derive maximum value from their investment. Understandably, there is considerable attention on primary and secondary endpoints, but trials present an opportunity to gain a host of other insights that could directly impact the ultimate success of a development program.

A good example of patient-centered evidence at work within trials is the use of in-trial interviews. These can take place at different study timepoints and provide insights with respect to treatment expectations and experiences, perceived changes, tolerability concerns, product acceptability or convenience, and unmet needs. They can also help address barriers to recruitment and trial design optimization for future study phases. They are particularly valuable in rare diseases and oncology where many existing outcome measures are poorly validated or do not reflect the reality of newly emerging interventions.

For companies with limited available budgets, it is not simply a question of whether additional evidence would be useful, but whether an opportunity to gather data that will be needed downstream has been missed. A modest patient-centered outcome component included from the outset may completely avoid the necessity for expensive evidence generation activities in the future.

Are you ready for the final hurdle?

For smaller companies, HTA evidence requirements can seem like a distant concern. However, decisions made in earlier phases can have significant consequences for the ability to adequately meet these needs. Appropriately selected instruments to assess concepts such as quality of life, functional impact, and patient and/or caregiver burden can be essential in adequately demonstrating product value. Attempting to address questions around the meaningfulness of observed changes or the clinical relevance of findings without the necessary data will only serve to undermine the value proposition of a product.

Patient-centered outcomes play an integral role in helping establish the link between clinical effects and outcomes that are relevant to patients and healthcare systems. They serve to inform economic modeling and health utility estimation, contextualize burden of disease, and demonstrate unmet need. When integrated appropriately they help significantly de-risk market access efforts and strengthen the overall value narrative.

How can we help?

A good patient-centered outcomes strategy will help answer a number of key questions. What concepts are important to patients? What outcomes are likely to occur with treatment? Which measures are appropriate and will meet regulatory standards? What degree of change is meaningful? Where would qualitative, preference, or satisfaction data strengthen the value argument and support product differentiation, labeling, reimbursement, and communication? Patient-centered outcomes are not a “nice to have” but rather an important tool in gathering evidence to support how a product improves patient outcomes and why it should be made accessible to those who would benefit.

Lumanity has a dedicated team of experienced patient-centered research professionals who are familiar with the unique challenges faced by smaller companies. We understand that resources are often limited, timelines are accelerated, investor expectations evolve, and decisions are often made before a full regulatory or commercial pathway is made clear. Our approach is to work with you in a lean, pragmatic fashion and to help ensure that you are best placed to succeed in a challenging and constantly changing global marketplace.

Lumanity helps biotech and pharma clients to ensure that the patient perspective is meaningfully integrated through the product development lifecycle. We offer a range of services that include:

Measurement & Endpoint Strategy

• Clinical outcomes assessment instrument development and modification
• Psychometric evaluation and validation
• Electronic clinical outcomes assessment development and equivalence studies

Evidence Generation

• In-trial interviews
• Natural history studies
• Surveys
• Preference studies
• Health utility studies

Synthesis & Interpretation

• Literature review
• Gap analysis
• Delphi panels

Regulatory & Access

• Regulatory strategy
• Dossier submissions
• Scientific communications